Last reviewed · How we verify
HX575 epoetin alfa Hexal AG
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.
HX575 is a biosimilar epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Anemia in patients with HIV infection.
At a glance
| Generic name | HX575 epoetin alfa Hexal AG |
|---|---|
| Also known as | Binocrit, Abseamed |
| Sponsor | Sandoz |
| Drug class | Erythropoiesis-stimulating agent (ESA); biosimilar |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for red blood cell production. By activating erythropoietin receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation, increasing hemoglobin and hematocrit levels. HX575 is a biosimilar formulation developed by Hexal AG (Sandoz) intended to be therapeutically equivalent to reference epoetin alfa products.
Approved indications
- Anemia of chronic kidney disease
- Chemotherapy-induced anemia
- Anemia in patients with HIV infection
Common side effects
- Hypertension
- Thrombotic events (venous thromboembolism, stroke)
- Headache
- Injection site reactions
- Pure red cell aplasia (rare)
Key clinical trials
- Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients (PHASE3)
- Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HX575 epoetin alfa Hexal AG CI brief — competitive landscape report
- HX575 epoetin alfa Hexal AG updates RSS · CI watch RSS
- Sandoz portfolio CI